Advertisement
(Logo: http://photos.prnewswire.com/prnh/20040705/CNM002LOGO )
(Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO )
"We are pleased that ISS, Glass Lewis and Proxy Governance all recognizethe merit of this unique combination for WuXi and are advising WuXishareholders to approve it," said Dr. Ge Li, Chairman and CEO of WuXiPharmaTech. "We remain fully committed to this transaction and urge ourshareholders to vote their shares for the proposed acquisition."
Advertisement
WuXi shareholders should immediately complete and return their proxy cardor submit proxies by telephone or through the Internet. Shareholders withquestions about the combination or how to vote their shares may contact thecompany's proxy solicitor, MacKenzie Partners Inc., toll-free, at (800) 322-2885.
About WuXi PharmaTech
WuXi PharmaTech is a leading pharmaceutical, biotechnology and medicaldevice R&D outsourcing company, with operations in China and the United States.As a research-driven and customer-focused company, WuXi PharmaTech provides abroad and integrated portfolio of laboratory and manufacturing servicesthroughout the drug and medical device R&D process. WuXi PharmaTech's servicesare designed to assist its global partners in shortening the cycle andlowering the cost of drug and medical device R&D. WuXi PharmaTech's operatingsubsidiaries are known as WuXi AppTec. For more information, please visit:http://www.wuxiapptec.com .
Forward-Looking Statements
This press release includes "forward-looking statements" within themeaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as "anticipate,""believe," "expect," "estimate," "plan," "outlook," and "project" and othersimilar expressions that predict or indicate future events or trends or thatare not statements of historical matters. These statements are based oncurrent expectations and beliefs of WuXi PharmaTech (Cayman) Inc. ("WuXi"),and involve a number of risks and uncertainties that could cause actualresults to differ materially from those stated or implied by the forward-looking statements. Those risks and uncertainties include, but are not limitedto: 1) the possibility that the proposed combination may be delayed or notcompleted due to the failure to obtain stockholder or regulatory approvals orotherwise satisfy the conditions to the proposed combination as set forth inthe acquisition agreement for the proposed combination; 2) problems may arisein successfully integrating the businesses of the two companies (includingretention of key executives); 3) the acquisition may involve unexpected costs;4) the combined company may be unable to achieve the expected transactionbenefits, including improved customer service levels and anticipated cost andrevenue synergies, or achieve potential revenue growth and non-GAAP marginexpansion; 5) the businesses may suffer as a result of uncertainty surroundingthe acquisition; and 6) the industry may be subject to future regulatory orlegislative actions and other risks that are described in Securities andExchange Commission ("SEC") reports filed or furnished by WuXi. For additionalinformation on these and other important factors that could adversely affectWuxi's business, financial condition, results of operations and prospects, see"Risk Factors" beginning on page 6 of WuXi's Annual Report on Form 20-F forthe fiscal year ended December 31, 2009, filed at the SEC's websitewww.sec.gov.
Because forward-looking statements involve risks and uncertainties, actualresults and events may differ materially from results and events currentlyexpected by WuXi. WuXi assume no obligation and expressly disclaim any duty toupdate information contained in this document except as required by law.
Additional Information
This press release is not a solicitation of proxies from WuXi'sshareholders to approve the proposed combination. In connection with theproposed transaction, WuXi has filed a scheme document with the SEC on Form 6-K. Before making any voting or investment decisions, WuXi's shareholders areurged to read the scheme document and any other relevant documents filed withthe SEC because they will contain important information. The scheme documenthas been mailed to WuXi's shareholders seeking their approval of the proposedcombination. WuXi's shareholders may also obtain a copy of the scheme documentfree of charge by directing a request to: WuXi PharmaTech (Cayman) Inc., 288Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, People'sRepublic of China, Attention: Genyong Qiu. In addition, the scheme document isavailable free of charge at the SEC's website, www.sec.gov. WuXi'sshareholders may also access copies of the documents filed with the SEC byWuXi on WuXi's website at http://www.wuxiapptec.com.
This press release does not constitute an offer of any securities for saleor a solicitation of an offer to buy any securities. The Charles River sharesto be issued in the proposed transaction have not been and will not beregistered under the Securities Act of 1933, as amended (the "Securities Act"),and may not be offered or sold in the United States absent registration or anapplicable exemption from registration requirements. Charles River intends toissue such Charles River shares pursuant to the exemption from registrationset forth in Section 3(a)(10) of the Securities Act.For more information, please contact: WuXi: Ronald Aldridge Director of Investor Relations, WuXi Phone: +1-201-585-2048 Email: [email protected] Sard Verbinnen & Company George Sard/Brandy Bergman/Jonathan Doorley Phone: +1-212-687-8080 Email: [email protected]
SOURCE WuXi PharmaTech (Cayman) Inc.
